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Purpose The purpose of the present phase II study was to evaluate both the efficacy and 
toxicity of the combination of S-1 and docetaxel in previously treated patients with 
locally advanced or metastatic non-small cell lung cancer. 
Methods Thirty-eight previously treated patients with non-small cell lung cancer were 
treated with S-1 (80 mg/m2, days 1–14, oral) and docetaxel (40 mg/m2, day 1, 
intravenous) every 3 weeks. 
Results No complete response was observed, and seven patients had a partial response, 
yielding an overall response rate of 18.4% (95% CI, 7.7-34.3%). The median overall 
survival time and 1-year overall survival rate were 16.1 months and 60%, respectively. 
The median progression-free survival time was 4.4 months. Myelosuppression was the 
main toxicity with grade 3 or 4 neutropenia and leukopenia in 50% and 21%, 
respectively. There was no irreversible toxicity in this study. 
Conclusions The combination of S-1 and docetaxel is well tolerable and has substantial 
activity for patients with locally advanced or metastatic non-small cell lung cancer. A 












Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths 
worldwide, but only a minority of patients is amenable to surgical or definitive 
chemoradiotherapy. The overall prognosis of NSCLC patients remains poor; only 15.2% 
patients are alive after 5 years [1]. Almost all patients eventually experience 
progression during or after treatment. Second-line chemotherapy with docetaxel 
showed modest antitumor activity, with overall response rate (ORR) of 6.7-7.1%, and 
can prolong survival after failure of platinum-based regimens for NSCLC, with a 1-year 
overall survival (OS) rate of 21–31% [2, 3]. However, despite current evidences 
supporting the use of second-line chemotherapy, the modest survival benefits, the 
negligible low response rate and relevant toxicity may reduce the role of second-line 
chemotherapy in clinical settings. 
S-1 (Taiho Pharmaceutical Co., Ltd.,, Tokyo, Japan) is an oral fluoropyrimidine 
agent comprising the 5-fluorouracil (5-FU) prodrug tegafur and two enzyme inhibitors, 
5-chloro-2,4-dihydroxypyrimidine (CDHP) and potassium oxonate (OXO), in a molar 
ratio of 1:0.4:1. CDHP enhances the serum 5-FU concentration by competitive inhibition 
of dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for 5-FU catabolism. 
OXO is a reversible competitive inhibitor of orotate phosphoribosyl transferase (OPRT), 
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a phosphoenzyme for 5-FU and reduces the gastrointestinal toxicity of 5-FU [4]. These 
mechanisms mean that oral S-1 administration can generate a higher concentration of 
5-FU than protracted intravenous injection of 5-FU alone, while the incidence of toxicity 
in the gastrointestinal tract does not increase. 
The combination of S-1 and docetaxel holds particularly great promise because 
both drugs have substantial antitumor activity as single agents, and they have different 
mechanisms of action and different toxicity profiles [2, 3, 5–7]. Recent preclinical 
studies have shown that S-1 has synergistic effects in human cancer xenografts [8–10]. 
The low level of DPD, thymidylate synthase activities, and a high level of OPRT activity 
enhance the antitumor effect of 5-FU and S-1. Docetaxel is one of the agents that 
modulate these enzyme expressions and activities. A phase I/II study has shown that 
this combination was well tolerated with moderate toxicities and promising activity in 
patients with gastric cancer [11]. Therefore, we conducted a phase II study to evaluate 
both the efficacy and toxicity of S-1 combined with docetaxel in previously treated 
patients with locally advanced or metastatic NSCLC. 
 
 




Eligible patients were aged 20–74 years and had histologically or cytologically 
confirmed locally advanced or metastatic NSCLC (stages IIIB–IV or relapse after 
surgery) that progressed after first- or second-line chemotherapy or chemoradiotherapy. 
The patients were required to have measurable disease by the Response Evaluation 
Criteria in Solid Tumors (RECIST), an Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of 0 or 1, ability to take oral medication and normal ECG. 
Eligibility requirements also included a white blood cell count of ≤12,000 cells/mL, an 
absolute neutrophil count of ≥2000 cells/mL, a platelet count of ≥100,000 cells/mL, a 
hemoglobin level of ≥9 g/dL, a serum total bilirubin level of ≤1.5 mg/dL, a serum 
aspartate aminotransferase (AST)/alanine aminotransferase (ALT) of less than or equal 
to twice the upper limit of normal, a serum creatinine level of ≤1.5 mg/dL and a normal 
electrocardiogram. Prior thoracic radiotherapy was allowed as long as it had been 
completed at least 12 weeks prior to inclusion and the patient had recovered from any 
toxicity. At least 4 weeks had to have elapsed from prior surgery and completion of prior 
chemotherapy or chemoradiotherapy. Patients who had exhibited evidence of severe 
heart or pulmonary disease or concomitant malignancy were excluded. The protocol was 
approved by the Ethics Committee of Kyoto University, and every patient gave written 
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informed consent. This trial was registered at University hospital Medical Information 
Network, Japan (protocol ID number, UMIN000000501 at http://www.umin.ac.jp/). 
 
Treatment plan 
S-1 was given orally twice daily for 2 weeks, followed by a drug-free interval of 
1 week (one cycle). Dose of S-1 administered each time was calculated according to the 
patient’s body surface area as follows: less than 1.25m2, 40mg; 1.25-1.5m2, 50mg; and 
greater than 1.5m2, 60mg. Docetaxel intravenous infusion (40 mg/m2) was administered 
on day 1. The treatment regimen was repeated every 3 weeks until disease progression 
or intolerable toxicity occurred. For patients who experienced febrile neutropenia, 
hemorrhage with grade 3 or 4 thrombocytopenia, or grade 3 or 4 non-hematologic 
toxicity, the dose of docetaxel was to be reduced to 35 mg/m2 and the dose of S-1 was also 
to be reduced to 80% of the initial dose. For patients who still experienced the same 
toxicity after the dose reduction, S-1 was to be reduced to 80% of the reduced dose, and 
this could be done up to twice.  If recovery from such toxicities at a reduced dose was 
confirmed, administration at the reduced dose was continued. Patients who still 




 Evaluation of response and toxicity 
Patients underwent tumor assessments at baseline and every 6 weeks by 
investigators using RECIST. Patient survival was observed until death, loss to follow up, 
or study closure. Adverse events were recorded using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (version 3). 
 
Statistical analysis 
The primary end point was the ORR as assessed in all eligible and treated 
patients, with success being defined as a complete response (CR) or partial response 
(PR) according to RECIST. The secondary endpoints were OS, progression-free survival 
(PFS) and adverse events. The design of this study was based on a binomial distribution 
with no planned interim analysis. Assuming a null hypothesis of a 9% ORR and an 
alternative hypothesis of a 25% ORR, with one-sided type I error=0.1 and type II 
error=0.1, it was necessary to enroll a minimum of 35 patients. According to this, we 
aimed for 40 patients to take non-evaluable patients into consideration. 
Exact confidence interval (CI) and exact P-value for ORR were based on the 
binomial distribution. OS was calculated from the date of registration until death from 
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any cause, whereas PFS until disease progression or death from any cause. OS and PFS 
were analyzed using the Kaplan–Meier method. All statistical tests were one-sided, and 
a P-value of less than 0.05 was considered statistically significant. All analyses were 




Between August 2006 and December 2007, 42 patients were enrolled in this 
study according to the eligibility criteria. Thirty-nine of these 42 patients were eligible, 
of the remainder one patient had stage IIIA NSCLC and two patients were without 
adequate liver function. Following the study protocol, one eligible but untreated patient 
was excluded from the analysis because of the incidence of a compression fracture 
caused by osteoporosis before treatment. Baseline characteristics of the 38 patients are 
summarized in Table 1. The median age was 65 years (range, 44–74 years). The 
majority of patients had an ECOG PS of 0 (95%), had been histologically or cytologically 
diagnosed as having adenocarcinoma (79%) and had progressed after at least one 
previous platinum-based chemotherapy regimen (92%). The median number of courses 






Tumor response results are shown in Table 2. Among all treated patients, no 
CR was observed and seven patients had a PR, yielding an ORR of 18.4% (95% CI, 
7.7–34.3%; P=0.05 under the null hypothesis of a 9% ORR). Among the patients with 
adenocarcinoma, PR was observed in 4/30 (13.3%). As shown in Figure 1, the median OS 
time was 16.1 months and the 1-year OS rate was 60% (95% CI, 42.5–73.6%). The 
1-year OS rates in stage-IIIB patients, stage-IV patients and patients with relapse after 
surgery were 70, 42 and 80%, respectively. The median PFS time was 4.4 months, and 
the 1-year PFS rate was 37% (Figure 1).   
 
Safety 
The major adverse events are shown in Table 3. The most frequent 
hematological toxicity was neutropenia with grade 3 or 4 neutropenia observed in 50% 
of patients. Of these events, grade 4 neutropenia was observed in seven patients (18%) 
and febrile neutropenia in one patient (3%). Grade 3 or 4 leukopenia was reported in 
21% of patients. The non-hematological grade 3 toxicities were anorexia in five patients 
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(13%), stomatitis in four patients (11%), hand-foot skin syndrome in two patients (5%), 
diarrhea in two patients (5%) and vomiting in one patient (3%). There was no death or 





Almost all patients with advanced NSCLC treated with first-line 
chemotherapy experience progression, and current options for the second-line 
treatment of NSCLC include single-agent chemotherapy with docetaxel, pemetrexed or 
erlotinib [12], which large-scale randomized clinical trials indicate as the standard 
regimen. However, the clinical responses to these agents are of short duration, and the 
survival benefit is limited. 
Many reports have been published investigating combination chemotherapy 
using two non-platinum agents for recurrent NSCLC in randomized clinical trials, with 
the objective of improving outcomes further. However, none of these studies have 
demonstrated improved survival with combination chemotherapy, whereas there have 
been relatively higher or intolerable toxicities [13–16]. Therefore, more active regimens 
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for the second-line chemotherapy are much needed. 
In the present study, we evaluated the efficacy and safety of the combination of 
S-1 and docetaxel, two agents that separately have shown promise in the treatment of 
advanced or metastatic NSCLC. This combination chemotherapy conferred efficacy with 
an ORR of 18%, a median OS time of 16 months and a 1-year OS rate of 60%.  The 18% 
ORR observed in this study was slightly lower than expected. However, the survival 
benefits as second- or third-line therapy observed compare favorably with other 
chemotherapy regimens, such as monotherapy with docetaxel (6–14 months) [2, 3, 7], 
pemetrexed (8 months) [17], erlotinib (6–15 months) [18–20] or oral topotecan (6–8 
months) [21, 22], or combination chemotherapy of irinotecan and cisplatin (11 months) 
[23], or oral fluoropyrimidine UFUR and gemcitabine (13 months) [24], although 
between-study comparisons should be made with caution. 
Prolonged survival may be due to substantial post-study treatment, 
especially epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). 
Although EGFR mutation status was not analyzed in this study, 17 patients received 
EGFR-TKIs and 9 of those patients for over a month. 
The hematological toxicity observed here was minimal and tolerable, despite 
the fact that grade 3 or 4 neutropenia occurred in 50%, which is comparable with the 
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toxicity caused by docetaxel monotherapy. The majority of non-hematologic toxicities 
were mild and tolerable without grade 4 non-hematologic toxicity. These toxicity results 
are consistent with those observed in a phase I/II study in patients with gastric cancer 
[11]. 
During the preparation of this manuscript, Atagi et al. [25] reported the results 
of a phase I/II study, in which the combination of S-1 and docetaxel was evaluated for 
patients who had failed one or more prior chemotherapy regimens. In the phase II part 
of their study, seven of 29 eligible patients achieved a PR, yielding an ORR of 24%, with 
a median OS time and the 1-year OS rate of 12 months and 42%, respectively. Patient 
characteristics were similar except for stage and ECOG PS: fewer patients who had 
experienced relapse after surgery were included, and 31% and 69% patients had ECOG 
PS of 0 and 1, respectively, in the study by Atagi et al. [25]. Although these differences 
in patient characteristics may lead to more favorable survival results in our study, the 
combination of S-1 and docetaxel still seems to be consistently promising as a 
chemotherapy option after the failure of prior chemotherapy for advanced NSCLC. 
In this study, the dose of docetaxel was lower than that commonly used in 
docetaxel monotherapy. As a second-line docetaxel monotherapy, a dose of 75 mg/m2 
every 3 weeks is used in the United States and Europe, and the dose is 60 mg/m2 every 3 
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weeks in Japan. However, our regimen is widely recognized as a tolerable and optimized 
combination of S-1 and docetaxel in gastric cancer [11], and thus, also in lung cancer, it 
is considered promising in terms of toxicity and efficacy. Furthermore, it was the 
recommended dose in the phase I part of study reported by Atagi et al. [25]. 
There are many report of ethnic differences in the safety and efficacy profile of 
S-1 and docetaxel [25–28], and it is shown that CYP2A6*9 genetic polymorphism is a 
potential predictive marker, for efficacy and toxicity, for the patients received the 
combination of S-1 and docetaxel for metastatic gastric carcinoma [29]. In the 
development of a S-1/docetaxel combination therapy in the United States and Europe, 
further optimization of the dose of each agent may be required to account for these 
differences. 
In conclusion, the combination of S-1 and docetaxel is well tolerable and 
promisingly effective for patients with locally advanced or metastatic NSCLC. A phase 
III trial comparing docetaxel with or without S-1 would warrant further investigation. 
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 Table 1. Patient characteristics (n=38) 
 
 No. of patients (%) 
Median age 65 years; range, 44–74 years 
Gender 
 Male 23 (61%) 
 Female 15 (40%) 
Histology 
 Adenocarcinoma 30 (79%) 
 Squamous Cell Carcinoma 4 (11%) 
 Others 4 (11%) 
Stage 
 IIIB 10 (26%) 
 IV 18 (47%) 
 Relapse after surgery 10 (26%) 
  IIIBa 3 (8%) 




 0 36 (95%) 
 1 2 (5%) 
Smoking history 
 Current/Former 24 (63%) 
 Never 14 (37%) 
Number of previous chemotherapy regimens 
 1 23 (61%) 
 2 15 (39%) 
Previous chemotherapy 
 Platinum-containing  35 (92%) 
 Gefitinib  7 (18%) 
 
ECOG PS, Eastern Cooperative Oncology Group performance status. 




 Table 2. Overall response rates according to RECIST (n=38) 
 
CR PR SD PD NE ORR  
 0 7 25 6 0 18.4% (95% CI, 7.7–34.3%) 
 
RECIST response evaluation criteria in solid tumors, CR complete response, PR partial 
response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall 




 Table 3. Adverse effects according to National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 3) (n=38) 
 
Toxicity All grades   Grade 3 or 4   
 No. (%) No. (%)  
Hematological toxicity 
 Neutropenia 31 (82%) 19 (50%) 
 Leukopenia 22 (58%) 8 (21%) 
 Anemia 18 (47%) 1 (3%) 
 Thrombocytopenia 3 (8%) 0 
 Febrile neutropeniaa 1 (3%) 1 (3%) 
Gastrointestinal toxicity 
 Stomatitis 33 (87%) 4 (11%) 
 Nausea 17 (45%) 0 
 Vomiting 7 (18%) 1 (3%) 
 Diarrhea 2 (5%) 2 (5%) 
Metabolic/Laboratory 
 AST 15 (39%) 0 
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 Hyperbilirubinemia 10 (26%) 1 (3%) 
 ALT 10 (26%) 0 
 Hypercreatinemia 3 (8%) 0 
Other toxicity 
 Anorexia 25 (66%) 5 (13%) 
 Hand-foot skin reaction 25 (66%) 2 (5%) 
 Fatigue 24 (63%) 0 
 Hyperpigmentation 8 (21%) - 
 Weight loss 4 (11%) 0 
 Pneumonitis 2 (5%) 0  
AST, aspartate aminotransferase; ALT, alanine aminotransferase. 






Legend for the figure 
 
Figure 1: Kaplan–Meier survival curves demonstrating overall (solid line) and 
















# Patients at risk
Months 0 6 12 18 24
OS 38 35 22 9 2
PFS 38 14 3 1 0
